Hyponatremia in Hospitalized Patients: The Potential Role of Tolvaptan

References

• . Palmer BF, Gates JR, Lader M. Causes and management of hyponatremia. Ann Pharmacother. 2003;37(11):1694–1702
   PubMed Web of Science ®Google Scholar
• . Waikar SS, Mount DB, Curham GC. Mortality and hospitalization with mild, moderate, and severe hyponatremia. Am J Med. 2009;122(9):857–865
   PubMed Web of Science ®Google Scholar
• . Zilberberg MD, Exuzides A, Spalding J, . Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients. Curr Med Res Opin. 2008;24(6):1601–1608
   PubMed Web of Science ®Google Scholar
• . Hawkins RC. Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Acta. 2003;337(1–2):169–172
   PubMed Web of Science ®Google Scholar
• . Hoorn EJ, Lindemans J, Zietse R. Development of severe hyponatremia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol Dial Transplant. 2006;21(1):70–76
   PubMed Web of Science ®Google Scholar
• . Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med. 2006;119(7 suppl 1):S30–S35
   PubMed Web of Science ®Google Scholar
• . Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342(21):1581–1589
   PubMed Web of Science ®Google Scholar
• . Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med. 1967;42(5):790–806
   PubMed Web of Science ®Google Scholar
• . Verbalis JG. AVP receptor antagonists as aquaretics: review and assessment of clinical data. Cleve Clin J Med. 2006;73( suppl 3):S24–S33
   PubMedGoogle Scholar
• . McKinley MJ, Mathai ML, McAllen RM, . Vasopressin secretion: osmotic and hormonal regulation by the lamina terminalis. J Neuroendocrinol. 2004;16(4):340–347
   PubMed Web of Science ®Google Scholar
• . Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007;120(11 suppl 1):S1–S21
   PubMed Web of Science ®Google Scholar
• . Wald R, Jaber BL, Price LL, Upadhyay A, Madias NE. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med. 2010;170(3):294–302
   PubMedGoogle Scholar
• . Asadollahi K, Hastings IM, Beeching NJ, Gill GV. Laboratory risk factors for hospital mortality in acutely admitted patients. Q J Med. 2007;100(8):501–507
   Google Scholar
• . Gill G, Huda B, Boyd A, . Characteristics and mortality of severe hyponatremia—a hospital-based study. Clin Endocrinol. 2006;65(2):246–249
   PubMed Web of Science ®Google Scholar
• . Whelan B, Bennett K, O'Riordan D, Silke B. Serum sodium as a risk factor for in-hospital mortality in acute unselected general medical patients. Q J Med. 2009;102(3):175–182
   Google Scholar
• . Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290(19):2581–2587
   PubMed Web of Science ®Google Scholar
• . Shorr AF, Tabak YP, Johannes RS, Gupta V, Saltzberg MT, Costanzo MP. Burden of sodium abnormalities in patients hospitalized for heart failure. Congest Heart Fail. 2011;17(1):1–7
   PubMedGoogle Scholar
• . Borroni G, Maggi A, Sangiovanni A, Cazzaniga M, Salerno F. Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients. Digest Liver Dis. 2000;32(7):605–610
   Web of Science ®Google Scholar
• . Jenq CC, Tsai MH, Tian YC, . Serum sodium predicts prognosis in critically ill cirrhotic patients. J Clin Gastroenterol. 2010;44(3):220–226
   PubMed Web of Science ®Google Scholar
• . Berghmans T, Paesmans M, Body JJ. A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. Support Care Cancer. 1999;8(3):192–197
   Web of Science ®Google Scholar
• . Dimopoulos K, Diller GP, Petraco R, . Hyponatremia: a strong predictor of mortality in adults with congenital heart disease. Eur Heart J. 2010;31(5):595–601
   PubMed Web of Science ®Google Scholar
• . Nair V, Niederman MS, Masani N, Fishbane S. Hyponatremia in community-acquired pneumonia. Am J Nephrol. 2007;27(2):184–190
   PubMed Web of Science ®Google Scholar
• . Forfia PR, Mathai SC, Fisher MR, . Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am J Resp Crit Care Med. 2008;177(12):1364–1369
   PubMed Web of Science ®Google Scholar
• . Scherz N, Labarère J, Méan M, Ibrahim SA, Fine MJ, Aujesky D. Prognostic importance of hyponatremia in patients with acute pulmonary embolism. Am J Respir Crit Care Med. 2010;182(9):1178–1183
   PubMed Web of Science ®Google Scholar
• . Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology. 2005;41(1):32–39
   PubMed Web of Science ®Google Scholar
• . Kim WR, Biggins SW, Kremers WK, . Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359(10):1018–1026
   PubMed Web of Science ®Google Scholar
• . Kamath PS, Wiesner RH, Malinchoc M, . A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–470
   PubMed Web of Science ®Google Scholar
• . Huo TI, Lee SD, Lin HC. Selecting an optimal prognostic system for liver cirrhosis: the model for end-stage liver disease and beyond. Liver Int. 2008;28(5):606–613
   PubMed Web of Science ®Google Scholar
• . Heuman DM, Abou-Assi SG, Habib A, . Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology. 2004;40(4):802–810
   PubMed Web of Science ®Google Scholar
• . Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl. 2005;11(3):336–343
   PubMed Web of Science ®Google Scholar
• . Chawla A, Sterns RH, Nigwekar SU, Cappuccio JD. Mortality and serum sodium: do patients die from or with hyponatremia? Clin J Am Soc Nephrol. 2011;6(5):960–965
   PubMed Web of Science ®Google Scholar
• . Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med. 2006;119(1):71.e1–71.e8
   Google Scholar
• . Kinsella S, Moran S, Sullivan MO, Molloy MG, Eustace JA. Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clin J Am Soc Nephrol. 2010;5(2):275–280
   PubMed Web of Science ®Google Scholar
• . Hoorn EJ, Rivadeneira F, van Meurs JB, . Mild hyponatremia as a risk factor for fractures: The Rotterdam Study [published online ahead of print March 4, 2011]. J Bone Miner Res
   Google Scholar
• . Gankam Kengne F, Andres C, Sattar L, Melot C, Decaux G. Mild hyponatremia and risk of fracture in the ambulatory elderly. QJM. 2008;101(7):583–588
   PubMed Web of Science ®Google Scholar
• . Huda MS, Boyd A, Skagen K, . Investigation and management of severe hyponatremia in a hospital setting. Postgrad Med J. 2006;82(965):216–219
   PubMed Web of Science ®Google Scholar
• . Whyte M, Down C, Miell J, Crook M. Lack of laboratory assessment of severe hyponatremia is associated with detrimental clinical outcomes in hospitalized patients. Int J Clin Pract. 2009;63(10):1451–1455
   PubMed Web of Science ®Google Scholar
• . Ayus JC, Arieff AI. Chronic hyponatremic encephalopathy in postmenopausal women: association of therapies with morbidity and mortality. JAMA. 1999;281(24):2299–2304
   PubMed Web of Science ®Google Scholar
• . Ayus JC, Achinger SG, Arieff A. Brain cell volume regulation in hyponatremia: role of sex, age, vasopressin, and hypoxia. Am J Physiol Renal Physiol. 2008;295(3):F619–F624
   PubMed Web of Science ®Google Scholar
• . Douglas I. Hyponatremia: why it matters, how it presents, how we can manage it. Cleve Clinic J Med. 2006;73( suppl 3):S4–S12
   PubMedGoogle Scholar
• . Zenenberg RD, Carluccio AL, Merlin MA. Hyponatremia: evaluation and management. Hosp Pract (Minneap). 2010;38(1):89–96
   PubMedGoogle Scholar
• . Bissram M, Scott FD, Liu L, Rosner MH. Risk factors for symptomatic hyponatraemia: the role of pre-existing asymptomatic hyponatraemia. Intern Med J. 2007;37(3):149–155
   PubMed Web of Science ®Google Scholar
• . Rachoin JS, Cerceo EA. Four nephrology myths debunked. J Hosp Med. 2011;6(5):E1–E5
   PubMed Web of Science ®Google Scholar
• . Sterns RH, Nigwekar SU, Hix JK. The treatment of hyponatremia. Semin Nephrol. 2009;29:282–299
   PubMed Web of Science ®Google Scholar
• . Sterns RH, Cappuccio JD, Silver SM, Cohen EP. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol. 1994;4(8):1522–1530
   PubMed Web of Science ®Google Scholar
• . Vu T, Wong R, Hamblin PS, Zajac J, Grossman M. Patients presenting with severe hypotonic hyponatremia: etiologic factors, assessment, and outcomes. Hosp Pract (Minneap). 2009;37(1):128–136
   PubMedGoogle Scholar
• . Vaidya C, Ho W, Freda BJ. Management of hyponatremia: providing treatment and avoiding harm. Cleve Clin J Med. 2010;77(10):715–726
   PubMed Web of Science ®Google Scholar
• . Sherlock M, Thompson CJ. The syndrome of inappropriate antidiuretic hormone: current and future management options. Eur J Endocrinol. 2010;162( suppl 1):S13–S18
   PubMed Web of Science ®Google Scholar
• . Yamamura Y, Nakamura S, Itoh S, . OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral doses in rats. J Pharmacol Exp Ther. 1998;287(3):860–867
   PubMed Web of Science ®Google Scholar
• . Schrier RW, Gross P, Gheorghiade M, ; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355(20):2099–2112
   PubMed Web of Science ®Google Scholar
• . Samsca™ (tolvaptan) tablets for oral use [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; May 2009
   Google Scholar
• . Verbalis JG, Adler S, Schrier RW, . Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol. 2011;164(5):725–732
   PubMed Web of Science ®Google Scholar
• . Gheorghiade M, Konstam MA, Burnett JC Jr, ; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure. The EVEREST Clinical Status Trials. JAMA. 2007;297(12):1332–1343
   PubMed Web of Science ®Google Scholar
• . Konstam MA, Gheorghiade M, Burnett JC Jr, ; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure. The EVEREST Outcome Trial. JAMA. 2007;297(12):1319–1331
   PubMed Web of Science ®Google Scholar
• . Pang PS, Konstam MA, Krasa HB, ; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J. 2009;30(18):2233–2240
   PubMed Web of Science ®Google Scholar
• . Gheorghiade M, Gottlieb SS, Udelson JE, ; Tolvaptan Investigators. Vasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol. 2006;97(7):1064–1067
   PubMed Web of Science ®Google Scholar
• . Berl T, Quittnat-Pelletier F, Verbalis JG, ; SALTWATER Investigators. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010;21(4):705–712
   PubMed Web of Science ®Google Scholar
• . Callahan MA, Do HT, Caplan DW, Yoon-Flannery K. Economic impact of hyponatremia in hospitalized patients: a retrospective cohort study. Postgrad Med. 2009;121(2):186–191
   PubMed Web of Science ®Google Scholar
• . Shea AM, Hammill BG, Curtis LH, Szczech LA, Schulman KA. Medical costs of abnormal serum sodium levels. J Am Soc Nephrol. 2008;19(4):764–770
   PubMed Web of Science ®Google Scholar
• . Cyr PL, Slawsky KA, Olchanski N, . Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. Am J Health Syst Pharm. 2011;68(4):328–333
   PubMed Web of Science ®Google Scholar